Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Alliance Pharmaceuticals
Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB
Telephone: +44 (0)1249 466 966
Fax: +44 (0)1249 466 977
WWW: http://www.alliancepharma.co.uk
Medical Information e-mail: medinfo@alliancepharma.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 04/06/2008
SPC Biorphen

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 04/06/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
Date of revision of text on the SPC:   28-May-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 4.4 - Avoid abrupt withdrawal of treatment - has been added.
Updated on 19/06/2007 and displayed until 04/06/2008
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   06/2007
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company
Section 4.3 - the following sentence was added

Hypersensitivity to orphenadrine, or to any of the excipients.

 
Section 4.4- the following sentence was added

 Contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
Updated on 07/07/2003 and displayed until 19/06/2007
Reasons for adding or updating:
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
Updated on 16/01/2003 and displayed until 07/07/2003
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 29/04/2002 and displayed until 16/01/2003
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Updated on 16/07/2001 and displayed until 29/04/2002
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 12/07/2001 and displayed until 16/07/2001
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 19/02/2001 and displayed until 12/07/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/03/2000 and displayed until 19/02/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 06/03/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  orphenadrine